A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Legend Biotech Corp stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 177,227 shares of LEGN stock, worth $7.09 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
177,227
Previous 162,555 9.03%
Holding current value
$7.09 Million
Previous $7.2 Million 19.96%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$43.55 - $59.88 $638,965 - $878,559
14,672 Added 9.03%
177,227 $8.64 Million
Q2 2024

Jul 19, 2024

SELL
$39.5 - $57.22 $79,711 - $115,469
-2,018 Reduced 1.23%
162,555 $7.2 Million
Q1 2024

Apr 19, 2024

BUY
$55.06 - $69.99 $79,451 - $100,995
1,443 Added 0.88%
164,573 $9.23 Million
Q4 2023

Jan 30, 2024

BUY
$57.25 - $69.74 $1.28 Million - $1.56 Million
22,376 Added 15.9%
163,130 $9.82 Million
Q3 2023

Oct 30, 2023

SELL
$63.16 - $76.5 $148,362 - $179,698
-2,349 Reduced 1.64%
140,754 $9.45 Million
Q2 2023

Jul 31, 2023

BUY
$46.28 - $75.01 $182,667 - $296,064
3,947 Added 2.84%
143,103 $9.88 Million
Q1 2023

Apr 27, 2023

BUY
$43.42 - $57.37 $867,748 - $1.15 Million
19,985 Added 16.77%
139,156 $6.71 Million
Q4 2022

Jan 30, 2023

BUY
$38.8 - $55.46 $312,068 - $446,064
8,043 Added 7.24%
119,171 $5.95 Million
Q3 2022

Oct 21, 2022

BUY
$38.15 - $57.1 $328,547 - $491,745
8,612 Added 8.4%
111,128 $4.53 Million
Q2 2022

Jul 26, 2022

BUY
$33.54 - $55.0 $154,720 - $253,715
4,613 Added 4.71%
102,516 $5.64 Million
Q1 2022

Apr 27, 2022

BUY
$31.02 - $48.18 $716,779 - $1.11 Million
23,107 Added 30.89%
97,903 $3.56 Million
Q4 2021

Feb 02, 2022

BUY
$41.14 - $56.98 $3.08 Million - $4.26 Million
74,796 New
74,796 $3.49 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.7B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Sumitomo Mitsui Trust Holdings, Inc. Portfolio

Follow Sumitomo Mitsui Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.